



12th European Headache Federation Congress



28-30 September 2018
Florence

Palazzo dei Congressi

www.ehf2018.com

Auditorium

07:00 - 08:00 **REGISTRATION**

08:00 - 09:00 **INDUSTRY SPONSORED SESSION - Non CME Session**

09:00 - 09:30 **GREPPI AWARD 2018**

Chair: *P. Martelletti (Rome, Italy), F. Pierelli (Rome, Italy)*

“Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials” - *D. Magis (Liège, Belgium)*

(M. Lisicki, K. D’Ostilio, G. Coppola, F. Scholtes, A. Maertens de Noordhout, V. Parisi, J. Schoenen, D. Magis)

09:30 - 10:30 **INFLAMMATION**

Chair: *R. Burstein (Boston, USA)*

Pain regulation by non-neuronal cells and inflammation – *R-R Ji (Durham, USA)*

What is the evidence for role of inflammation in migraine? Why do NSAIDs work so effectively in acute treatment – *M. Ashina (Copenhagen, Denmark)*

Imaging inflammation in animal models of migraine – *A. Schain (Boston, USA)*

10:30 - 11:00 **COFFEE BREAK & e-POSTER DISCUSSION**

11:00 - 12:00 **ADDICTION: IS MEDICATION OVERUSE (HEADACHE) A FORM OF ADDICTION?**

Chair: *Z. Katsarava (Unna, Germany)*

Neurobiology of addiction – *Y. Shaham (Baltimore, USA)*

Is MO(H) a form of addiction? Is it unique to migraine patients? Why? – *C. Tassorelli (Pavia, Italy)*

12:00 - 13:00 **COMPARING CEPHALIC AND NON-CEPHALIC PAIN IN ADOLESCENTS AND ADULTS**

Chair: *M. Ashina (Copenhagen, Denmark)*

Challenging two SS’s in pain chronification – *D. Borsook (Boston, USA)*

Differences and similarities observed in functional imaging of headache studies – *A. Hougaard (Copenhagen, Denmark)*

13:00 - 14:00 **BREAK & e-POSTER DISCUSSION**

14:00 - 15:00 **INDUSTRY SPONSORED SESSION - CME Accredited**

15:00 - 16:00 **THE COMORBID RELATIONSHIP BETWEEN MIGRAINE AND EPILEPSY**

Chair: *R. Burstein (Boston, USA)*

The comorbid relationship between migraine and epilepsy. – *R.B. Lipton (New York, USA)*

Is there a genetic link between migraine and epilepsy? – *G. Terwindt (Leiden, The Netherlands)*

Seizure activates the trigeminovascular system differently than CSD: implications to differences between post-ictal headache and migraine – *A. Melo-Carrillo (Boston, USA)*

Auditorium

16:00 - 16:30 **EMA REGULATORY SCIENCE IN MIGRAINE**

Chair: *P. Martelletti (Rome, Italy)*

Sharing medicines information in the European Medicines Agency regulatory network
– *J. Garcia-Burgos (London, UK)*

The EMA-EHF *Documento* for migraine – *P. Martelletti (Rome, Italy)*

16:30 - 17:30 **OPENING CEREMONY**

Chairs: *P. Martelletti (Rome, Italy), R. Burstein (Boston, USA)*

LECTURE Fifty years of Norwegian contribute to headache research – *L. Stovner (Trondheim, Norway)*

EHF LECTURE: Targeting metabotropic glutamate receptors in the treatment of chronic pain – *F. Nicoletti (Rome, Italy)*

WELCOME COCKTAIL

Sala Verde

08:00 - 09:00 **EHF-SCHOOL OF ADVANCED STUDIES**

09:00 - 10:30 **ORAL PRESENTATIONS (N=9)**

10:30 - 11:00 **COFFEE BREAK AND e-POSTER DISCUSSION**

11:00 - 12:00 **IS MIGRAINE ASSOCIATED WITH STRUCTURAL BRAIN CHANGES?**

Chair: *D. Borsook (Boston, USA)*

MRI studies can predict progression of disease years before it occurs – *R. Messina (Milan, Italy)*

MRI studies cannot predict progression of disease years before it occurs – *D. Gaist (Odense, Denmark)*

12:00 - 13:00 **ORAL PRESENTATIONS (N=6)**

13:00 - 14:00 **BREAK & e-POSTER DISCUSSION**

14:00 - 15:00 **BRAINSTEM AURA**

Chair: *A. Ducros (Montpellier, France)*

Brainstem aura is real – *J. Olesen (Copenhagen, Denmark)*

Brainstem aura is not real – *A. Ducros (Montpellier, France)*

Auditorium

08:00 - 08:40 **GENETIC VS ENVIRONMENTAL**

Chair: *C. Lampl (Linz, Austria)*

Migraine onset in childhood is a genetic disease – *A. Hershey (Cincinnati, USA)*

Migraine in childhood is an environmental disease – *V. Guidetti (Rome, Italy)*

08:40 - 09:20 **OCCIPITAL HEADACHE**

Chair: *D.D. Mitsikostas (Athens, Greece)*

Occipital migraine and the cerebellum – *R. Nosedà (Boston, USA)*

Occipital migraine and muscle tenderness – *L. Bendtsen (Copenhagen, Denmark)*

09:20 - 10:00 **POST-TRAUMATIC HEADACHE**

Chair: *M. Linde – (Trondheim, Norway)*

Post-traumatic headache is a unique headache disorder – *M. Linde (Trondheim, Norway)*

Novel insight into post-traumatic headache – *G. Ifergane (Omer, Israel)*

10:00 - 11:00 **INDUSTRY SPONSORED SESSION - Non CME Session**

11:00 - 11:30 **COFFEE BREAK AND e-POSTER DISCUSSION**

11:30 - 13:00 **NEUROPHARMACOLOGY OF MIGRAINE**

Chair: *A. Maassen van den Brink (Rotterdam, The Netherlands)*

The CGRP family of peptides – *L. Edvinsson (Lund, Sweden)*

Gender aspect of CGRP in migraine – *A. Maassen van den Brink (Rotterdam, The Netherlands)*

Serotonin (triptans and ditans) & dopamine: mode of action (PET & clinical trials data) – *U. Reuter (Berlin, Germany)*

Reproducibility of biochemical markers (neuropeptides, neurosteroids) in primary headache – *P. Geppetti (Florence, Italy)*

13:00 - 14:00 **BREAK & E-POSTER DISCUSSION**

14:00 - 15:00 **INDUSTRY SPONSORED SESSION - Non CME Session**

15:00 - 16:00 **EMERGING TARGETS FOR TREATMENT - APART FROM CGRP**

Chair: *S. Silberstein (Philadelphia, USA)*

Cannabinoids: endogenous and exogenous; hope or bluster? – *S. Silberstein (Philadelphia, USA)*

PAC1, PACAP – *A.L. Vollesen (Copenhagen, Denmark)*

K_{ATP} channels – *M. Al-Kharagholi (Copenhagen, Denmark)*

Auditorium

16:00 - 18:00 RE-READING BURNING TOPICS

Chairs: *D.D. Mitsikostas (Athens, Greece), M. Braschinsky (Tartu, Estonia)*

Placebo is a universal problem, it is just that expectation response in adults creates a window for small but significant therapeutic effect – *D.D. Mitsikostas (Athens, Greece)*

Novel views in Idiopathic Intracranial Hypertension – *A. Sinclair (Birmingham, UK)*

RCVS and cerebral vasculitis – *A. Steinberg (Stockholm, Sweden)*

Imaging in headache experimental research – *F. Amin (Copenhagen, Denmark)*

What have we learned from cellular and circuit mechanisms of the primary brain dysfunctions that cause familial hemiplegic migraine? – *D. Pietrobon (Padua, Italy)*

Manual approach to tension-type headache. Is this a reliable approach? – *C. Fernández-de-Las-Peñas (Madrid, Spain)*

Sala Verde

08:00 - 09:00 EHF-SCHOOL OF ADVANCED STUDIES

09:00 - 10:00 NEUROPHYSIOLOGY OF THE MIGRAINE BRAIN

Chair: *Z. Katsarava (Unna, Germany)*

The migraine brain is inheritably hyper-responsive – *D. Magis (Liège, Belgium)*

The migraine brain is not hyper-responsive – *T. Sand (Thronheim, Norway)*

10:00 - 11:00 ORAL PRESENTATIONS (N=6)

11:00 - 11:30 COFFEE BREAK AND e-POSTER DISCUSSION

11:30 - 13:00 ORAL PRESENTATIONS (N=9)

13:00 - 14:00 BREAK & e-POSTER DISCUSSION

14:00 - 15:00 INDUSTRY SPONSORED SESSION - Non CME Session

15:00 - 16:00 THE BLOOD BRAIN BARRIER

Chair: *C. Ayata (Boston, USA)*

The BBB opens up during migraine – *C. Ayata (Boston, USA)*

The BBB does not open during migraine – *F. Amin (Copenhagen, Denmark)*

16:00 - 17:00 EHF-SCHOOL OF ADVANCED STUDIES

Sala Onice

09:00 - 10:00 **TEACHING COURSE**

MIGRAINE AND HORMONES

Chair: *A. Maassen van den Brink (Rotterdam, The Netherlands)*

Hormonal contraceptives: *how they impact on migraine course* – *S. Sacco (L'Aquila, Italy)*

Hormonal contraceptives in women with migraine: *pros and cons* – *E.A. MacGregor (London, United Kingdom)*

10:00 - 11:00 **TEACHING COURSE**

PRECISION MEDICINE IN COMPLEX MIGRAINE PATIENTS

Chair: *P. Martelletti (Rome, Italy)*

Precision Medicine general concept in clinical practice – *M. Simmaco (Rome, Italy)*

Metabolomics and Therapeutic Drug Monitoring: a routine tool – *L. Lionetto (Rome, Italy)*

Three dimensional approach for DDI evaluation in Precision Medicine – *P. Martelletti (Rome, Italy)*

11:00 - 11:30 **COFFEE BREAK AND e-POSTER DISCUSSION**

11:30 - 13:00 **TEACHING COURSE**

ARBORIZATIONS OF CORTICAL SPREADING DEPRESSION

Chair: *R. Burstein (Boston, USA)*

History of SD and migraine – *M. Lauritzen (Glostrup, Denmark)*

Electrophysiological mechanisms of SD: from channels to extracellular potential shifts –
D. Pietrobon (Padua, Italy)

SD susceptibility as a drug screening tool – *C. Ayata (Boston, USA)*

SD as a trigger for headache – *R. Burstein (Boston, USA)*

13:00 - 14:00 **BREAK & E-POSTER DISCUSSION**

14:00 - 15:00 **TEACHING COURSE**

PERIPHERAL INTERVENTIONAL MANAGEMENT OF REFRACTORY HEADACHES

Chair: *G. Lambu (London, UK)*

Head and neck nerves blockade – *A. Özge (Mersin, Turkey)*

Sphenopalatine ganglion and trigger points blockade – *D. Uludüz (Istanbul, Turkey)*

15:00 - 16:00 **EHF - IHS TEACHING COURSE**

THE BROAD SPECTRUM OF SECONDARY HEADACHES

Chairs: *M. Ashina (Copenhagen, Denmark), P. Martelletti (Rome, Italy)*

Sports and headache – *R. Evans (Houston, USA)*

Headache attributed to non-vascular intracranial disorder
– *R. Jensen (Copenhagen, Denmark)*

Headaches associated with eye diseases – *A. Sinclair (Birmingham, UK)*

Cluster headache-like – *G. Lambu (London, UK)*

16:00 - 17:00 **EHF-SCHOOL OF ADVANCED STUDIES**

Auditorium

08:00 - 09:00 SECONDARY HEADACHES

Chair: *C. Lampl (Linz, Austria)*

The secondary headaches: a *cul de sac* for the headache expert? – *C. Lampl (Linz, Austria)*

Managing secondary headaches with a multimodal expertise – *H. Schytz (Copenhagen, Denmark)*

09:00 - 10:00 EHF 2018 GUIDELINES ON MIGRAINE TREATMENT

Chair: *P. Martelletti (Rome, Italy)*

EHF Guidelines on the use of CGRP(r) MAbs in migraine – *S. Sacco (L'Aquila, Italy)*

EHF Guidelines on the use of OnabotulinumtoxinA in migraine – *L. Bendtsen (Copenhagen, Denmark)*

10:00 - 11:00 HEADACHE COST, HEADACHE CARE: FINDING BALANCE IN EUROPE

Chair: *T.J. Steiner (London, UK)*

Counting cost: disability and lost productivity – *T.J. Steiner (London, UK)*

Providing care: cost-effective and affordable – *M. Tinelli (London, UK)*

Providing care: migraine medication and a mishandled market: errors that undermine care – *Z. Katsarava (Unna, Germany)*

11:00 - 11:30 COFFEE BREAK AND e-POSTER DISCUSSION

11:30 - 12:30 CLUSTER HEADACHE: WHO IS THE CULPRIT?

Chair: *K. Paemeleire (Ghent, Belgium)*

Do we have new approaches to cluster headache? – *K. Paemeleire (Ghent, Belgium)*

Do we treat cluster headache correctly? – *M. Matharu (London, UK)*

12:30 - 13:30 CLOSING

Chairs: *P. Martelletti, R. Burstein, D.D. Mitsikostas*

EHF-SAS 2018 Fellowship Awards

EHF Athens 2019 Congress Presentation

Sunday, 30 September 2018

Sala Verde

08:00 - 09:00 EHF - SCHOOL OF ADVANCED STUDIES

10:00 - 11:00 ORAL PRESENTATIONS (N=6)

11:00 - 11:30 COFFEE BREAK AND e-POSTER DISCUSSION

11:30 - 13:00 ORAL PRESENTATIONS (N=9)

SALA VERDE

09:00 - 10:30 **01** - New pharmacology, expression profiles and probes of CGRP receptors - *Debbie Hay*

02 - Efficacy, Safety, and Tolerability of Orally Administered Atogepant for the Prevention of Episodic Migraine: Results from a Phase 2b/3 Study - *Peter J. Goadsby, David W. Dodick, Joel M. Trugman, Michelle Finnegan, Hassan Lakkis, Kaifeng Lu, Armin Szegedi*

03 - Alterations in CGRP and PACAP38 levels in cluster headache - *Agneta Snoer, Anne Luise Haulund Vollesen, Rasmus Paulin Beske, Song Guo, Jan Hoffmann, Jan Fahrenkrug, Niklas Rye Jørgesen, Torben Martinussen, Rigmor Højland Jensen, Messoud Ashina*

04 - Medication overuse in a post-hoc analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine - *Sheena K Aurora, Paula A Morrow, Dustin D Ruff, Eric Pearlman*

05 - Study CGAL: a placebo-controlled study of galcanezumab in patients with episodic cluster headache: results from the 8-week double-blind treatment phase - *James M. Martinez, Peter J. Goadsby, David Dodick, Jennifer N. Bardos, Tina M. Myers Oakes, Brian A. Millen, Chunmei Zhou, Sherie A. Dowsett, Sheena K. Aurora, Jyun Yan Yang, Robert R. Conley, Massimo Leone*

011 - Migraine induction with calcitonin gene-related peptide in patients from erenumab trials - *Casper Emil Christensen, Samaira Younis, Marie Deen, Sabrina Khan, Hashmat Ghanizada, Messoud Ashina*

017 - Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low- versus high-frequency of migraine headaches - *Virginia L Stauffer, Stephen Silberstein, Virginia L Stauffer, Katie Day, Qi Zhang, Sarah Lipsius, Maria Carmen Wilson*

018 - Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies - *Qi Zhang, Sheena K. Aurora, Qi Zhang, Virginia L. Stauffer*

019 - Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies - *Apeksha Rao, Grazia Dell'Agnello (Presenter), Antje Tockhorn-Heidenreich, Qi Zhang, Dustin D. Ruff, Eric M. Pearlman, Sheena K. Aurora, Janet H. Ford*

SALA VERDE

12:00 - 13:00 **031** - Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine - *Virginia Stauffer, Kathleen A. Day, Michael Ament, Virginia L. Stauffer, Vladimir Skljarevski, Qi Zhang, Eric M. Pearlman, Sheena K. Aurora*

032 - Factors associated with significant reduction in migraine headache days: a post hoc analysis of phase 3 placebo-controlled trials of patients with episodic and chronic migraine treated with galcanezumab - *Qi Zhang, Sheena K. Aurora, Dustin D. Ruff, Qi Zhang, Eric M. Pearlman*

033 - Effect of galcanezumab on possible menstrual-related migraine: exploratory analyses results from EVOLVE-1, EVOLVE-2 and REGAIN - *Sheena Aurora, Maria S. Fernandes, Holland C. Detke, Qi Zhang, elena M. Pavlovic, Sheena K. Aurora*

038 - Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication - *Paul K. Winner, Rashmi B. Halker Singh, Joshua M. Cohen, Ronghua Yang, Paul P. Yeung, Verena Ramirez Campos*

039 - Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication - *Stephen D. Silberstein, Jessica Ailani, Joshua M. Cohen, Ronghua Yang, Paul P. Yeung, Verena Ramirez Campos*

040 - Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication - *Peter McAllister, David W. Dodick, Joshua M. Cohen, Ronghua Yang, Paul P. Yeung, Verena Ramirez Campos*

SALA VERDE

10:00 - 11:00 **06** - Migraine with prolonged aura: a rare and peculiar condition? Results from a prospective diary-aided study - *Michele Viana, Grazia Sances G, Mattias Linde, Giuseppe Nappi, Peter Goadsby and Cristina Tassorelli.*

07 - Ten factors associated to migraine chronification: a cross-sectional study on 318 long-term migraine sufferers - *Michele Viana, Sara Bottiroli, Grazia Sances, Giuseppe Nappi, Cristina Tassorelli*

09 - White matter microstructure changes in migraine: a diffusional kurtosis imaging study - *Sait Ashina, Bettina Conti, Benjamin Ades-Aron, Yvonne Lui, Mia Minen, Dmitry Novikov, Timothy Shepherd, and Els Fieremans*

010 - Meningeal contribution to migraine pain: a 3T magnetic resonance angiography study - *Sabrina Khan, Faisal Mohammad Amin, Casper Emil Christensen, Hashmat Ghanizada, Samaira Younis, Anne Christine Rye Andersen, Patrick J H de Koning, Henrik B W Larsson, Messoud Ashina*

012 - Incidence, clinical characteristics and long-term course of headache in patients with stroke (DMKG multicenter study) - *Thomas Dresler, Sarah Dietrich, Andrea Düring, Daniel Rothkirch, Filipp Filippopoulos, Ozan Eren, Andre-as Straube, Stephan Zierz, Gudrun Goßrau, Torsten Kraya*

013 - Headache in transient ischemic attacks - *Elena Lebedeva, Natalia M. Gurary, Jes Olesen*

SALA VERDE

- 11:30 - 13:00 **026** - Searching for a neural signature of hallowdymia in migraine: a volumetric MRI study - *Francesca Pistoia, Claudia Marsecano, Antonio Carolei, Riccardo Cornia, Luana Evangelista, Alessandra Splendiani, Simona Sacco*
- 027** - Dopaminergic symptoms in migraine: a case series on 1148 patients - *P. Barbanti, P. Ferroni, G. Egeo, L. Fofi, C. Aurilia*
- 030** - Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy - *Kerry Kniewel, Louise Lombard, Andrew Buchanan, Simin Baygani, Joel Raskin, Joshua Tobin*
- 034** - Primary angiitis of the central nervous system and reversible cerebral vasoconstriction syndrome. A comparative study of two cohorts - *Hubert de Boysson, Jean-Jacques Parienti, Jérôme Mawet, Caroline Arquizan, Grégoire Boulouis, Cécilia Burcin, Olivier Naggara, Mathieu Zuber, Emmanuel Touzé, Achille Aouba, Marie-Germaine Bousser, Christian Pagnoux, Anne Ducros*
- 035** - Validation of the Italian Version of the "Identify Chronic Migraine" screening tool: The IT-EC-ID - *S. Sacco, S. Benemei, S. Cevoli, G. Coppola, P. Cortelli, F. De Cesaris, R. De Icco, C. De Marco, C. Di Lorenzo, L. Evangelista, P. Geppetti, A. Manni, A. Negro, G. Pierangeli, F. Pierelli, L. Pellesi, L. A. Pini, F. Pistoia, M.P. Prudenzano, A. Russo, G. Sances, V. Taranta, C. Tassorelli, G. Tedeschi, M. Trojano, P. Martelletti*
- 036** - Migraine progression in natural subgroups of migraine based on comorbidities and concomitant conditions: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study - *Richard B. Lipton, Vincent T. Martin, Michael L. Reed, Cristina M. Fanning, Aubrey Manack Adams, Dawn C. Buse*
- 037** - Complete detoxification is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial - *Ida M S Engelstoft, Louise N Carlsen, Signe B Munksgaard, Mia Nielsen, Rigmor H Jensen, Lars Bendtsen*
- 041** - Cluster headache is not associated with sleep apnea or specific sleep stages - *N. Lund, M. Barloese, A. Snoer, A. Petersen, P. Jørgen Jennum, R.H.Jensen*
- 044** - CSF pressure fluctuations as a marker of isolated CSF hypertension in headache sufferers - *L. Rapisarda, G. Demonte, F. Tosto, M. Curcio, B. Vescio, C. Bombardieri, D. Mangialavori, U. Aguglia, A. Gambardella, F. Bono*

SALA VERDE

- 10:00 - 11:00 **08** - Long-term effects of the non-paralytic botulinum toxin A molecule BiTox in migraine animal models - *Anna Andreou, Ramla AbuukarAbdullahi, Joseph O. Lloyd, Martyn G Jones, Giorgio Lambru, Adnan Al-Kaisy, Bazbek Davletov, Anna P Andreou*
- 014** - Optimization of vagus nerve stimulation efficacy on cortical spreading depression - *Andreia Morais, Andreia Lopes de Morais, Tsubasa Takizawa, Inge Mulder, Tao Qin, BS1, Bruce Simon, Rubem Carlos Araujo Guedes, Cenk Ayata*
- 015** - DNA methylation pattern of CALCA gene in patients with migraine - *Elisa Rubino, Silvia Boschi, Alessandro Vacca, Salvatore Gentile, Lorenzo Pinessi, MariaTeresa Giordana, Innocenzo Rainero*
- 020** - Cephalic and extracephalic neurophysiological effects of botulinum toxin type A treatment in chronic migraine - *Gianluca Coppola, Francesca Cortese, Davide Di Lenola, Cherubino Di Lorenzo, Vincenzo Parisi, Francesco Pierelli.*
- 021** - Idiopathic Intracranial Hypertension: Consensus Guidelines on Management - *Susan Mollan, Davis B, Silver NC, Shaw S, Malucci C, Wakerley BR, Krishnan A, Chavda SV, Ramalingam S, Edwards J, Hemmings K PhD, Williamson M, Burdon MA, Hassan smith G, Digre K, Liu GT, Jensen RH, Sinclair AJ*
- 022** - Long-term outcomes after reversible cerebral vasoconstriction syndrome: recurrence, cardiovascular events and mortality in a prospective follow-up study - *Rosalie Boitet, Solène De Gaalon, Grégory Marin, Claire Duflos, Caroline Roos, Jérôme Mawet, Cécilia Burcin, Ursula Fiedler, Marie-Germaine Bousser et Anne Ducros*

SALA VERDE

- 11:30 - 13:00 **016** - The impact of chronic headache on workdays, unemployment and disutility in the general population - *Espen Saxhaug Kristoffersen, Knut Stavem, Christofer Lundqvist, Michael Bjørn Russell*
- 023** - Complete detoxification is the most effective in reducing disability in patients with medication-overuse headache: A randomized controlled open-label trial - *Louise Carlsen, Mia Nielsen, Louise N Carlsen, Rigmor H Jensen, Signe B Munksgaard, Ida M S Engelstoft, Lars Bendtsen*
- 024** - The economic and humanistic burden of episodic and chronic migraine in Europe - *Hicham Benhaddi, Timothy Fitzgerald, Sophie McCabe, Ruth Zeidman*
- 025** - Headache outcome measures in medically refractory chronic migraine patients treated with OnabotulinumtoxinA - *Manjit Matharu, Lagrata Susie, Ahmed Maha, Miller Sarah, Matharu Manjit*
- 028** - Non-invasive vagus nerve stimulation (nVNS) for the acute treatment of episodic migraine: additional findings from the randomised, sham-controlled, double-blind PRESTO trial - *Eric Liebler, Paolo Martelletti; Licia Grazzi; Giulia Pierangeli; Innocenzo Rainero; Pierangelo Geppetti; Anna Ambrosini; Paola Sarchielli; Piero Barbanti; Cristina Tassorelli; Eric Liebler; Marina de Tommaso*
- 029** - Tocilizumab in patients with giant cell arteritis: results from a Phase 3 randomized controlled trial - *Susan Mollan, Katie Tuckwell, Sophie Dimonaco, Micki Klearman, Neil Collinson, John H Stone*
- 042** - Real-world preventative drug management of Chronic Migraine among Spanish Neurologists - *David García-Azorín, Santos Lasaosa S, Gago-Veiga AB, Viguera Romero J, Guerrero-Peral AL, Pozo-Rosich P.*
- 043** - Effect of the H1-antihistamine clemastine on PACAP38 induced migraine - *Anne Luise Haulund Vollesen,*
- 045** - The practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) as an acute treatment for episodic migraine: a post hoc analysis of the randomised sham-controlled PRESTO trial - *Eric Liebler, Licia Grazzi; Cristina Tassorelli; Marina de Tommaso; Giulia Pierangeli; Paolo Martelletti; Innocenzo Rainero; Pierangelo Geppetti; Anna Ambrosini; Paola Sarchielli; Eric Liebler; Piero Barbanti*

SCREEN A

10:30 - 11:00 **P1** - The cost of migraine in Greece: a half billion euros disease - *Maria Kalogeropoulou, Panagiotis Stafyla, Marianthi Karaïskou, Eirini Tsiamakı, Maria Kalogeropoulou, Dimos-Dimitrios Mitsikostas*

P2 - Single-pulse transcranial magnetic stimulation (sTMS) for the treatment of migraine: a prospective real world experience - *Giorgio Lambru, Hill Bethany, Lloyd Joseph, Al Kaisy Adnan, Andreou Anna P*

P3 - The impact of fremanezumab on symptoms associated with migraine in patients with episodic migraine - *Jan Brandes, Jan L. Brandes, Paul P. Yeung, Ernesto Aycardi, Ronghua Yang, Yuju Ma, Joshua M. Cohen*

P4 - The impact of fremanezumab on symptoms associated with migraine in patients with chronic migraine - *Peter McAllister, Paul P. Yeung, Ernesto Aycardi, Ronghua Yang, Yuju Ma, Joshua M. Cohen*

P5 - Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study - *Jan Brandes, Paul P. Yeung, Joshua M. Cohen, Sanjay K. Gandhi, Timothy Fitzgerald, Ronghua Yang, Yuju Ma, Ernesto Aycardi*

SCREEN B

10:30 - 11:00 **P6** - Overview of fremanezumab pooled safety data from placebo-controlled phase 2 and 3 studies - *Stephen D. Silberstein, Nicola Faulhaber, Xiaoping Ning, Paul P. Yeung, Jimmy Schiemann, Ronghua Yang, Yuju Ma, Ernesto Aycardi*

P7 - Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment - *Joshua M. Cohen, Kristen Bibeau, Maja Galic, Michael J. Seminerio, Verena Ramirez Campos, Rashmi B. Halker Singh, Jessica Ailani*

P8 - Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication - *Peter J. Goadsby, David W. Dodick, Stephen D. Silberstein, Paul P. Yeung, Tricia Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Ma, Ernesto Aycardi, Marcelo E. Bigal*

P9 - The Effect of Cognitive Behavioural Therapy on Self-Efficacy and Headache Frequency, in Chronic Migraine - *Özlem Mercan, Ayhan Bingöl, Derya Uludüz, Özlem Mercan, Yasemin Akıncı, Duygu Deringöl, Sabahattin Saip, Aksel Siva*

SCREEN B

10:30 - 11:00 **P10** - Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression - *Joshua M. Cohen, Paul P. Yeung, Ernesto Aycardi, Marcelo E. Bigal, Ronghua Yang, Kristen Bibeau, Maja Galic, Michael J. Seminerio, Richard B. Lipton, Dawn C. Buse*

SCREEN C

10:30 - 11:00 **P11** - Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine - *Stephen D. Silberstein, Richard B. Lipton, Merle L. Diamond; Joshua M. Cohen, Ronghua Yang, Bo Jiang*

P12 - The impact of fremanezumab on medication overuse in patients with chronic migraine - *Stephen D. Silberstein, Sait Ashina, Zaza Katsarava, Kristen Bibeau, Michael J. Seminerio, Danielle E. Harlow, Joshua M. Cohen*

P13 - Work productivity amongst those with migraine: results from the My Migraine Voice survey - *Todd J. Schwedt, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Michel Lanteri-Minet, Hans-Christoph Diener, Annik K.-Laflamme, Elena Ruiz de la Torre, Audrey Craven, Annette Vangaa Rasmussen, Donna Walsh, Simon Evans, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo*

P14 - Headache following mild traumatic brain injury (MTBI) in a population-based, controlled, longitudinal study - *Lena Hoem Nordhaug*

P15 - A randomised, double-blind, placebo-controlled study of erenumab safety in patients with stable angina - *Christophe Depre, Lubomir Antalík, Amaal Starling, Michael Koren, Osaro Eisele, Daniel D Mikol*

SCREEN D

10:30 - 11:00 **P16** - Burden and patient-reported outcomes of migraine patients with prior prophylactic treatment failure: Study design of the multinational BECOME study - *Paolo Martelletti, Christian Lucas, Patricia Pozo-Rosich, David Watson, Charly Gaul, Emma Ramsden, Shannon Ritter, Josefin Snellman*

P17 - My Migraine Voice: a worldwide survey of 11,266 migraine patients - *Elena Ruiz de la Torre, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Todd J. Schwedt, Michel Lanteri-Minet, Hans-Christoph Diener, Annik K.-Laflamme, Annette Vangaa Rasmussen, Donna Walsh, Audrey Craven, Simon Evans, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo*

SCREEN D

10:30 - 11:00 **P18** - Economic burden of migraine: healthcare resource utilization in the My Migraine Voice survey - *Paolo Martelletti, Rebeca Quintana, Veruska Carboni, Todd J. Schwedt, Michel Lanteri-Minet, HansChristoph Diener, Annik K.-Laflamme, Elena Ruiz de la Torre, Audrey Craven, Simon Evans, Donna Walsh, Annette Vangaa Rasmussen, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo*

P19 - Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2 - *Virginia Stauffer, Qi Zhang, Paula A. Morrow, Virginia L Stauffer, Vladimir Skljarevski, Eric M. Pearlman, Sheena K Aurora*

P20 - Sustained efficacy over 1 year of treatment with erenumab: Results from the extension phase of the STRIVE study in episodic migraine - *Peter J Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Feng Zhang, Sandhya Sapra, Denise E Chou, Jan Klatt, Hernan Picard, Robert A Lenz, Daniel D Mikol*

SCREEN E

10:30 - 11:00 **P21** - Efficacy outcomes in responder and nonresponder patients with episodic migraine treated preventively with erenumab in the STRIVE study - *Gregor Brössner, Uwe Reuter, Jo H Bonner, David W Dodick, Hernan Picard, Shihua Wen, Shannon Ritter, Jan Klatt, Daniel D Mikol*

P22 - Efficacy of erenumab in patients with chronic migraine achieving $\geq 50\%$ response: Subgroup analysis of a double-blind, randomised study - *David Dolezil, Jan Klatt, Sunfa Cheng, Feng Zhang, Shihua Wen, Shannon Ritter, Daniel D Mikol*

P23 - Long-term safety and tolerability of erenumab: Three-plus year results from an ongoing open-label extension study in episodic migraine - *Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen Silberstein, David Dodick, Gregory A. Rippon, Jan Klatt, Feng Zhang, Sunfa Cheng, Daniel D. Mikol*

P24 - Assessment of the long-term safety and efficacy of erenumab during open-label treatment of subjects with chronic migraine - *Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Feng Zhang, Sunfa Cheng, Daniel Mikol*

P25 - Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine - *James M. Martinez, Sandra Garces, Greg Anglin, Michael Hodsdon, William Kielbasa, Brian A Moser, Eric Pearlman*

SCREEN A

- 13:00 - 14:00 **P26** - Lack of visual paired associative short-term plasticity in migraine patients between attacks - *Gianluca Coppola, Chiara Abagnale, Federico Ranieri, Clarissa Elizabeth Centurioni, Gabriella Musumeci, Fioravante Capone, Giovanni Di Pino, Vincenzo Parisi, Vincenzo Di Lazzaro, Francesco Pierelli.*
- P27** - Effect of OnabotulinumtoxinA on the Frequency and Impact of Headaches in Patients with Chronic Migraine with or without a History of Acute Pain Medication Overuse: Results of the COMPEL Study - *Stewart J. Tepper, MD, Maria-Carmen Wilson, MD, John F. Rothrock, MD, Amelia Orejudos, MsC, Aubrey Manack Adams, PhD, Andrew M. Blumenfeld, MD,*
- P28** - Body Mass Index and its relationship with disability, severity, duration and frequency of headaches in female migraine patients - *Faraidoon Haghdoost, Mansouerh Togha, Faraidoon Haghdoost, Faezeh Khorsha, Soodeh Razeghi Jahromi, Zeinab Ghorbani*
- P29** - Effect of propranolol in a non-invasive human model of trigeminovascular activation - *Eloísa Rubio-Beltrán, Rianne M. Schoon, Jeffrey vd Berg, Jorie Versmissen, A.H. Jan Danser, Anton H. van den Meiracker, Antoinette MaassenVanDenBrink*
- P30** - Effects of subthreshold single pulse Transcranial Magnetic Stimulation (sTMS) on activity of hypothalamic A11 region - *Joseph Lloyd, Dr M Jones, Prof S McMahon, R Abuukar Abdullahi, Dr AP Andreou*
- P31** - Intracranial pressure: A comparison of the non-invasive HeadSense monitor vs. lumbar pressure measurement - *Jeppe Hvedstrup, Jeppe Hvedstrup, Aleksandra Radojicic, Walid Moudrou, Martin W Herklots, Anton Wert, Manfred Holzgraefe, Mark Obermann, Guus G Schoonman, Rigmor H Jensen, Henrik W Schytz*
- P32** - Triptans use in post-dural puncture headache - *Federico Mainardi, Giorgio Zanchin, Carlo Lisotto, Ferdinando Maggioni*
- P33** - A case of autoimmune encephalitis preceded by posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome - *Jaeho Kim, Mi Ji Lee*
- P34** - New insights in post-traumatic cluster headache through a cohort study - *Grangeon Lou, Lou Grangeon, Emer O'Connor, Layan Akijian, Thanh Mai Pham, Manjit Matharu*

SCREEN A

13:00 - 14:00 **P35** - The relevance of associated symptoms of migraine according to migraine subtypes: A Clinical study - *Osman Özgür Yalın, Aynur Özge, Osman Özgür Yalın, Derya Uludüz, Özlem Mercan, Mehmet Ali Sungur, Aksel Siva*

SCREEN B

13:00 - 14:00 **P36** - Descriptive analysis of a population with chronic migraine in a tertiary Headache Center - *Luzeiro Isabel, Ana-Inês Martins, Joana Ramos-Lopes, Pedro Lopes, Bruno Silva, Sónia Batista, Lúvia Sousa, Isabel Luzeiro*

P37 - White matter lesions in chronic Migraine are related with molecular markers of inflammation and blood brain barrier disruption - *Clara Dominguez Vivero, C. Dominguez, M. Saavedra, X. Rodríguez-Osorio, T. Sobrino, F Campos, J. Castillo, R. Leira*

P38 - Iron deposits in periaqueductal gray matter are related with poor response to Onabotulinumtoxin A in chronic migraine - *Clara Dominguez Vivero, C. Dominguez, M. Saavedra, X. Rodríguez-Osorio, C. Villalba, P. Ramos-Cabrer, T. Sobrino, F Campos, J. Castillo, R. Leira*

P39 - Economic impact of migraine in the EU5: a matched analysis of the NHWS 2017 data on work productivity and healthcare resource use - *Pamela Vo, Michael J. Doane, Pamela Vo, Aikaterini Bilitou, Juanzhi Fang, Annik K-Laflamme, Shaloo Gupta*

P40 - Humanistic burden of migraine in the EU5: a matched analysis of the NHWS 2017 - *Pamela Vo, Michael J. Doane, Pamela Vo, Aikaterini Bilitou, Juanzhi Fang, Annik K-Laflamme, Shaloo Gupta*

P41 - Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine - *Linda Wietecha, Linda A. Wietecha, Bernice Kuca, Josephine Asafu-Adjei, Sheena K. Aurora*

P42 - Conversion from chronic to episodic migraine with erenumab, a specific inhibitor of the calcitonin gene-related peptide receptor - *Richard B Lipton, Stewart J Tepper, Stephen Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David Dodick, Feng Zhang, Gregory A Rippon, Daniel D Mikol*

P43 - Erenumab impact on patient-reported outcomes in chronic migraine in the presence of acute medication overuse - *Stewart J Tepper, Messoud Ashina, Jan Klatt, Pooja Desai, Feng Zhang, Sunfa Cheng, Daniel D Mikol*

SCREEN B

13:00 - 14:00 **P44** - Long-term efficacy of erenumab in patients with chronic migraine who failed prior prophylactic treatment - *Messoud Ashina, Stewart J Tepper, Jan L Brandes, Uwe Reuter, Guy Boudreau, David Doležil, Jan Klatt, Feng Zhang, Sunfa Cheng, Daniel D Mikol*

P45 - Changes in patient functioning and disability: results from two phase 3 double blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2) - *Jeffrey Carter, Janet H. Ford, David W. Ayer, Qi Zhang, Jeffrey N. Carter, Vladimir Skljarevski, Sheena K. Aurora*

SCREEN C

13:00 - 14:00 **P46** - 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies - *Eric Pearlman, Abraham Jim Nagy, Eric Pearlman; Dustin Ruff; Kathleen Day; Noah Rosen*

P47 - Diagnostic screeners for migraine: a methodological caveat - *Csaba Ertsey, Csépanyi É, Magyar M, Gyüre T, Bozsik Gy, Tóth M*

P48 - Comparison of personality traits and dependence behavior between MOH patients and illicit drug users - *Carlo Baraldi, Pellesi Lanfranco, Guerzoni Simona, Cainazzo Maria Michela, Lo Castro Flavia, Pini Luigi Alberto*

P49 - Validity and reliability Turkish Headache Impact Test (HIT-6) in patients with episodic and chronic migraine - *Pinar Yalınay Dikmen, P Yalınay Dikmen, M Bozdağ, M Gunes, S Kosak, B Tasdelen, D Uludüz, A Ozge*

P50 - Retrospective analysis of peripheral nerve block for the treatment of headaches and cranial neuralgias in the neurology section of a general hospital - *Vanesa Adell, Jessica García-Alhama, Sonia Jaraba, Joan Prat, Mariano Huerta*

P51 - Relationship between severity of migraine and Vitamin D deficiency: a case control study - *Laura Rapisarda, A.D. Montisano, A. Sarica, G. Demonte, F. Tosto, A. Gambardella, F. Bono*

P52 - A case-control study of visual-vestibular mismatch in childhood with primary headaches - *Carlo Baraldi, Daniele Monzani, Pellesi Lanfranco, Guerzoni Simona, Cainazzo Maria Michela, Lo Castro Flavia, Baraldi Carlo, Pini L Alberto*

SCREEN C

13:00 - 14:00 **P53** - Primary headaches associated with physical exertion - *Fusun Mayda Domaç, Sergül Zengin, Mehmet Fatih Demir*

P54 - Headache burden in the Emergency Room - *Aida Quka, A.Quka, O. Cibuku, I.Zekja, I. Xhura, J. Kruja*

P55 - Prevalence and risk factors of tension-type headache among adolescents in Kharkiv city (Ukraine) - *Kostiantyn Stepanchenko*

SCREEN D

P56 - Pediatric migraine: A new pediatric migraine-specific comorbidity index on prognosis - *Osman Ozgur Yalin, Didem Derici Yildirim, Bahar Tasdelen, Derya Uludüz, Aynur Özge, Osman Özgür Yalin, Saim Yologlu*

P57 - Characteristics of Isolated Headache patients in Cerebral Venous Sinus Thrombosis (CVST): The Results of VENOST – national survey - *Osman Ozgur Yalin, Derya Uludüz, Osman Özgür Yalin, Taskın Duman, Fusun Mayda Domaç, Serefnur Öztürk, Vildan Yayla, Ali Yavuz Karahan, Nazire Afsar, Mehmet Ali Sungur, VENOST Study Group*

P58 - One-year incidence of Chronic Migraine in Tertiary Headache Outpatient Clinics: A multi-center study - *Osman Ozgur Yalin, Aynur Özge, Derya Uludüz, Osman Özgür Yalin, Seden Demirci, Macit Selekler, Ali Akyol, Sebnem Bıçakçı, Vesile Öztürk, Musa Öztürk, Betül Baykan, Mehmet Ali Sungur, Aksel Siva*

P59- Vestibular Migraine presenting as an acute peripheral vestibulopathy: clinical and vestibular function test profiles - *Zeljka Calic, Rachael L Taylor, Allison Young, Leigh M McGarvie, Cecilia Cappelen-Smith, Denis Cordato, Miriam S Welgampola*

P60 - Headache in the Pediatric Emergency Department: proposal of diagnostic and therapeutic algorithm of management - *Roberta Rossi, Antonia Versace, Barbara Lauria, Giulia Grasso, Emanuele Castagno, Fulvio Ricceri, Rosaura Pagliero, Antonio Francesco Urbino*

P61 - Correlation between pediatric primary headache and specific learning disabilities: a case-control study - *Antonia Versace, Ausilia Enea, Antonia Versace, Barbara Lauria, Giulia Grasso, Roberta Rossi, Emanuele Castagno, Stefania Benetti, Veronica Sciannameo, Antonio Francesco Urbino*

SCREEN D

13:00 - 14:00 **P62** - Astrocytes contribute to the trigeminal central sensitization and cephalic cutaneous hypersensitivity in rat model of chronic migraine - *M. Megemont, A. Descheemaeker, R. Dallel, L. Monconduit and P. Luccarini*

P64 - Cortical excitability in chronic migraine patients after OnabotulinumtoxinA preventive treatment - *Vladlena Shevchenko, Ada Artemenko, Mikhail Bzhiljanski, Fedor Bushkov, Nikolay Yahno, Alexey Kurenkov*

P65 - Beyond the headache phase of a migraine attack: closer look at the burden of migraine phases – results from the worldwide My Migraine Voice survey - *Michel Lanteri Minet, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Todd J. Schwedt, Hans Christoph Diener, Annik K.-Laflamme, Elena Ruiz de la Torre, Audrey Craven, Simon Evans, Donna Walsh, Annette Vangaa Rasmussen, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo*

SCREEN E

13:00 - 14:00 **P68** - Demographic and clinical characteristics of patients with trigeminal neuralgia assisted by neurologists in an Emergency Department - *Javier Camiña Muñiz, Germán Ferrer Juan, María Magdalena Rosselló Vadell, Antonio José Moreno Rojas, Francisco José Molina Martínez*

P69 - Systematic review of the safety and efficacy of Occipital Nerve Stimulation for intractable chronic cluster headache - *Tinsley Jennifer, Iris Smet, Jean-Pierre Van Buyten, Michel Lanteri-Minet, Denys Fontaine, Jennifer Tinsley, Brooke Kelley*

SCREEN E

13:00 - 14:00 **P70** - Safety data from phase 3 clinical studies comparing galcanezumab and placebo in patients with episodic and chronic migraine - *Jeffrey Carter, Virginia L. Stauffer, Shufang Wang, Mark E. Bangs, Tina M. Oakes, Jeffrey N. Carter, Sheena K. Aurora*

P71 - OnabotulinumtoxinA: How and when do our patients improve? - *Alicia Alpuente Ruiz, A.Alpuente, VJ.Galla.rdo, M.Torres-Ferrús, J.Álvarez-Sabín, P.Pozo-Rosich*

P72 - The role of foods with a high glycemic index in migraine patients: a real life preliminary study - *Gianluca Cecchi, Gianluca Cecchi, Maria Bravo, Paola Di Caprio, Giorgia Botti, Nicoletta Brunelli, Matteo Paolucci, Manon Khazrai, Fabrizio Vernieri and Claudia Altamura*

P73 - Do evidence-based practice guidelines exist to support physiotherapists in the approach of patients with episodic headache? - *Sarah Mingels and Marita Granitzer*

P74 - Efficacy and safety of a sequential surgical algorithm in 44 patients with refractory chronic cluster headache - *Robert Belvís, Marina Guasch, Paula Marrero, Maria Jesus Alvarez, Rodrigo Rodríguez, Joan Molet, Carles Roig*

P75 - Spectral domain optical coherence tomography findings in RVCL-S, a monogenic vascular migraine model - *Irene de Boer, Sylvie R. Steenmeijer, Nadine Pelzer, Greet Dijkman, Irene C. Notting, Gisela M. Terwindt*

P130 - Efficient therapy for treatment of migraine without aura: ergotamine based drugs or sumatriptan - *Sinisa Miljkovic, Dz. Smajlovic, S. Crncevic, T. Jurisic, M. Tiric Campara, L. Duranovic Vinkovic, Z. Dostovic, Z. Pasic*

SCREEN A

11:00 - 11:30 **P76** - Life traumatic experiences and stressful events as predictors of detoxification therapy outcome at 6 months in chronic migraine with medication overuse - Sara Bottiroli, Bottiroli Sara, Sances Grazia, De Icco Roberto, Vito Bitetto, Guaschino Elena, Marta Allena, Pazzi Stefania, Giuseppe Nappi & Tassorelli Cristina

P77 - Role of transient receptor potential (TRP) channels in a rat model of trigeminal neuropathic pain: focus on TRPA1 channels - Chiara Demartini, Rosaria Greco, Anna Maria Zanaboni, Oscar Francesconi, Cristina Nativi, Cristina Tassorelli, Kristof Deseure

P78 - Meningeal contribution to migraine pain: a 3T magnetic resonance angiography study - Sabrina Khan, Faisal Mohammad Amin, Casper Emil Christensen, Hashmat Ghanizada, Samaira Younis, Anne Christine Rye Andersen, Patrick J H de Koning, Henrik B W Larsson, Messoud Ashina

P79 - Sex differences in vascular responses to CGRP - Alejandro Labastida-Ramírez, Eloísa Rubio-Beltrán, A. van den Bogaerdt, J. Schouten, A.H. Jan Danser, Carlos M. Villalón & Antoinette Maassen van den Brink

P80 - Effect of onabotulinumtoxinA prevention on comorbidities of depression and anxiety in chronic migraine: Analysis in headache day frequency responders vs headache day frequency non-responders - Andrew Blumenfeld, Stewart J. Tepper, Lawrence D. Robbins, Amelia Orejudos, Aubrey Manack Adams, Dawn C. Buse, Stephen D. Silberstein

SCREEN B

11:00 - 11:30 **P81** - Life with migraine, effect on relationships, career and finances, and overall health and well-being: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study - Dawn C. Buse, Sharron Murray, Paula K. Dumas, Aubrey Manack Adams, Michael L. Reed, Kristina M. Fanning, Richard B. Lipton

P82 - A multicenter, prospective, randomized, open-label study to compare onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine: patient reported functional outcomes from the FORWARD study - Andrew M. Blumenfeld, Atul T. Patel, Aubrey Manack Adams, John F. Rothrock

SCREEN B

11:00 - 11:30 **P83** - Headache attributed to psychiatric disorder - *Ana Lj Podgorac, Goran Gajic, Bojana Pejuškovic, Ljubica Zamurovic-Dunderovic, Vanja B Mandic-Maravic, Aleksandar Misojčić, Dušica M Lecic-Toševski*

P84 - Healthcare expenditure: does society give migraine the focus and recognition patients deserve? - *Parth Joshi, Leonhard Schaetz, Parth Joshi, Aoife Callan, Vivek Khurana, Jasper Huels*

P85 - Gender differences in clinical and pharmacological response to triptans - *Daphne S. van Casteren (in case the oral abstract is rejected), Tobias Kurth, Michel D. Ferrari, Gisela M. Terwindt, Antoinette Maassen van den Brink*

SCREEN C

11:00 - 11:30 **P86** - Migraine induction with calcitonin gene-related peptide in patients from erenumab trials - *Samaira Younis, Casper Emil Christensen, Samaira Younis, Marie Deen, Sabrina Khan, Hashmat Ghanizada, Messoud Ashina*

P87 - Mitochondrial DNA and migraine - *Sigrid Børte, Bendik S. Winswold, Lars G. Fritsche, Ida Surakka, Jonas B. Nielsen, Wei Zhou, Cristen J. Willer and John-Anker Zwart*

P88 - Headache in Call Center Employees: an Occupational Disease - *Jera Kruja, Ilir Alimehmeti, Xhovana Kane, Jera Kruja*

P90 - Psychosocial risk factors for headache - *M Zaletel, L Zaletel-Kragelj, B Žvan*

SCREEN D

11:00 - 11:30 **P91** - The prevalence and some risk factors chronic headache in Mongolia - *Selenge Enkhtuya, Otgonbayar Luvsannorov, Byambasuren Tsenddorj, Timothy J Steiner*

P92 - Symptoms of dependence in medication overuse headache: daily consumption versus days without consumption - *Azimova J, Skorobogatykh K, Amelin A*

P93 - Effectiveness and safety of OnabotulinumtoxinA in the treatment of chronic migraine in patients older than 65 - *María Castañón, E. Ameijide, J.M. Sánchez*

P94 - Headache education and management in a multi centric study Cameroon - *David García-Azorín, Kurtis Urra M, Molina M, Delgado-Suarez C, Iglesias García P, García-Morales I, Gonzalez-Monje M*

P95 - Non-compliance with follow-up: analysis of two years attendance to a second level headache centre in Italy - *Teresa Catarci, Isabella Falomi and Roberto Batistoni*

SCREEN E

11:00 - 11:30 **P96** - A real-world analysis of global patient reported outcomes in patients with migraine - *Janet H. Ford, Sarah Cotton, James Jackson, Jeffrey S. Andrews, Shonda A Foster, Wenyu Ye, Russell M. Nichols, Antje Tockhorn-Heidenreich*

P97 - ONAMIG: Does onabotulinumtoxinA modulate cortical excitability in chronic migraine? - *Alicia Alpuente Ruiz, N.Raguer, M.Torres-Ferrús; VJ. Gallardo, J. Álvarez-Sabín, P. Pozo-Rosich*

P98 - Effectiveness of OnabotulinumtoxinA in chronic migraine. If early introduction: faster, cheaper and more satisfactory - *Robert Belvis, Noemí Morollón, Marina Guasch, Paula Marrero, Azahara Aceituno, Carles Roig*

P99 - Sickness absence and disability pension in cluster headache patients and in matched references: a population-based study - *Anna Steinberg, Pontus Josefsson, Kristina Alexandersson, Christina Sjöstrand*

P100 - Clinical features of pediatric medication overuse headache and applicability of new ICHD-3 criteria - *Romina Moavero, Maddalena Stornelli, Laura Papetti, Barbara Battan, Samuela Tarantino, Federico Vigeveno, Massimiliano Valeriani*

SCREEN A

- 13:00 - 14:00 **P101** - C-tactile touch perception and habituation in migraineurs - *Lapp Hanna Sophie, Ilona Croy, Gudrun Gossrau*
- P102** - Endeavor to identify associations between vaping and primary headaches - *Marge Vaikjärv, Kati Toom, Mark Braschinsky*
- P103** - NDPH sub-categories and treatment in pediatrics patients - *Priyanka Shekhawat*
- P104** - Frequency, referral and demographic characteristics of patients with vestibular migraine from a tertiary centre - *Isabel Luzeiro*
- P105** - Migraine comorbidity and cognitive performance in patients with focal epilepsy - *Olivia Begasse de Dhaem, Chris Morrison, Kimford J Meador, Dale E Hesdorffer, Sabrina Cristofaro, Jacqueline French, Mia T Minen, on behalf of the HEP Investigators*
- P106** - Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia - *Mona Ameri Chalmer, Thomas Folkmann Hansen, Jes Olesen*
- P107** - Living with migraine: a report from the My Migraine Voice survey - *Audrey Craven, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Michel Lanteri Minet, Todd J. Schwedt, Hans-Christoph Diener, Annik K-Laflamme, Annette Vangaa Rasmussen, Elena Ruiz de la Torre, Donna Walsh, Simon Evans, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo*
- P108** - A model concept for assessing the cost-effectiveness of prophylactic migraine treatments - *Ronan Mahon, Pamela Vo, Philip Cooney, Andrii Danyliv, Aikaterini Bilitou, Nagasuman Toram, Sreelatha Vadapalle, Jasper Huels, Farooq Maniyar, Peter J. Goadsby, Mark Sculpher*
- P109** - Relative efficacy of outpatient infusion therapy on pediatric patients with post concussive headaches - *Sara Gould, Erin Mackenzie Katz, Carly Ann Cignetti*
- P110** - Movement disorders as positive motor aura symptoms during hemiplegic migraine attacks - *Elisa De La Cruz, Geneviève Demarquay, Caroline Roos, Isabelle Sabatier, Florence Riant, Victoria González, Anne Ducros*

SCREEN B

13:00 - 14:00 **P111** - Long-term response to onabotulinumtoxin A in chronic migraine: analysis of efficacy and tolerability in a series of 40 patients - *García-Azorín D, Sierra A, Trigo J, Martínez-Pías E, Guerrero AL.*

P112 - Acute and preventive treatment patterns and associated work productivity and activity impairment among patients with migraine in Germany - *Jeffrey Scott Andrews, Janet Ford, Grazia Dell'Agnello, Sarah Cotton, Antje Tockhorn-Heidenreich, Louise Lombard, Zoe Phillips, James Jackson*

P113 - Baseline demographics and disease characteristics of patients with episodic cluster headache: results from a phase 3 clinical trial - *James M. Martinez, Jennifer N. Bardos, Tina M. Myers Oakes, Chunmei Zhou*

P114 - PrevenBox: Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in migraine - *Marta Torres-Ferrus, Sonia Santos Lasaosa; Angel Guerrero Peral; Jose M Laínez; Javier Viguera Romero; Ana B Gago Veiga; Pablo Irimia; Margarita Sanchez del Río; Laila Asskour; Victor J Gallardo; Patricia Pozo-Rosich*

P115 - Onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data - *David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Ronald E. DeGryse, Aubrey Manack Adams, Hans-Christoph Diener*

P116 - New daily persistent headache: A systematic review on an enigmatic disorder - *Nooshin Yamani, Jes Olesen*

P117 - Clinical description of 135 patients with typical aura without headache and scale proposal for diagnosis in a first episode - *Robert Belvís, Marina Guasch, Paula Marrero, Noemí Morollón, Azahara Aceituno, Carles Roig*

P118 - Onabotulinumtoxin A for Chronic Migraine with Medication Overuse: Preliminary Clinical Results and Changes in Catastrophising - *Licia Grazzi, Eleonora Grignani, Emanuela Sansone, Alberto Raggi, Matilde Leonardi, Domenico D'Amico, Frank Andrasik*

P119 - Mindfulness meditation for migraine in pediatric population: a pilot study - *Licia Grazzi, Emanuela Sansone, Raggi Alberto, Eleonora Grignani, Matilde Leonardi, Chiara Scaratti, Frank Andrasik*

P120 - Prophylactic effect of ultramicronized N-Palmitoyl Ethanol Amide (PEA) on pediatric migraine: a preliminary study - *Giorgia Sforza, Laura Papetti, Samuela Tarantino, Barbara Battan, Michela Ada Noris Ferilli, Romina Moavero, Federico Vigeveno, Massimiliano Valeriani*

SCREEN C

13:00 - 14:00 **P121** - Cerebral Hemodynamics, Patent foramen ovale and White Matter Hyperintensities in patients Migraine with aura, young stroke patients and controls - *Altamura C, Mallio CA, Lo Vullo G, Brunelli N, Paolucci M, Cascio Rizzo A, Cecchi G, Quattrocchi CC, Vernieri F.*

P123 - Anxiety, depression and alexithymia in young migraine patients: which relationship with body weight? - *Samuela Tarantino, Alessandra di Stefano, Laura Papetti, Barbara Battan, Giorgia Sfronza, Federico Vigevano, Simonetta Gentile, Massimiliano Valeriani*

P124 - Health care resource use, sick-leaves and comorbidities among migraine patients in occupational health care - *Minna A. Korolainen, Samu Kurki, Iiro Toppila, Mariann Lassenius, Timo Purmonen and Markku Nissilä*

P125 - The Number of Active Trigger Points is Associated with Pain Features, Depression and Anxiety in Frequent Episodic, but not Chronic, Tension Type Headache - *César Fernández-de-las-Peñas, Stella Fuensalida-Novo, María Palacios-Ceña, Matteo Castaldo, Kelun Wang, Lars Arendt-Nielsen*

P126 - New daily persistent headache in a pediatric population - *Laura Papetti, Barbara Battan, Romina Moavero, Giorgia Sforza, Samuela Tarantino, Massimiliano Valeriani Headache Center Bambino Gesù Children Hospital, Rome Italy*

P127 - Cerebral vascular reactivity in patients with chronic neck pain - *Nevzat Uzuner, Aycan Guner Ekici, Gulnur Tekgol Uzuner, Sacit Gulec*

P128 - Chronic migraine is much more related to cardiovascular risk factors: a clinic based study - *Gulnur Tekgol Uzuner, Osman Ozgur Yalin, Derya Uluduz, Aynur Ozge, Nevzat Uzuner*

P129 - The “pure” Trochlear Migraine : two cases and nosographic considerations - *vincenzo raieli, Luca Maria Messina, Francesca Cardella, Rosaria Roppolo, Francesca Vanadia, Filippo Brighina, Vincenzo Raieli*

SCREEN D

13:00 - 14:00 **P131** - Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials - *Apeksha Rao, Russell M. Nichols (Presenter); Dustin Ruff; Eric Pearlman; Sheena K. Aurora, MD*

P132 - Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Post-hoc Analyses of Two Phase 3 Studies - *Apeksha Rao, Sheena K. Aurora, Holland C. Detke, Brian A. Millen, Hans-Peter Hundemer (Non-author presenter only)*

P133 - Migraine and cluster headache – the common link - *Anne Luise Vollesen*

P134 - Providing care: Cost-effective and affordable - *Michela Tinelli*

P135 - The Activity Impairment in Migraine – Diary (AIM-D): A novel migraine-specific patient-reported outcome measure to assess functioning based on activity impairment in episodic and chronic migraine patients - *Monica Elmore, ML Cala, CA Graham, RB Lipton, N Lyn, DW Dodick, C Burk, JS Yu, CJ Evans, HN Viswanathan*

P136 - Epidemiology of chronic and episodic migraine in Europe - *Hicham Benhaddi, Timothy Fitzgerald, Sophie McCabe, Ruth Zeidman*

P137 - The impact of offering monthly and quarterly dosing options for a new class of migraine preventive therapy on likelihood of acceptance and adherence in adults with migraine - *Ravi Iyer, Robert Cowan, Joshua Cohen, Erik Rosenman, Tim Fitzgerald, Ravi Iyer*

P138 - Prognosis of trigeminal neuralgia is very favourable when managed by specialists – a two-year prospective real-life study - *Tone Heinskou, Tone Bruvik Heinskou, Stine Maarbjerg, Frauke Wolfram, Per RoCHAT, Jannick Brennum, Jes Olesen and Lars Bendtsen*

P139 - Serum changes of apolipoproteins in Medication Overuse Headache (MOH) - *Lanfranco Pellesi, Elisa Bellei, Carlo Baraldi, Flavia, Simona Guerzoni, Emanuela Monari, Luigi Alberto Pini*

P140 - Robust association between Obstructive sleep apnea (OSA) and Idiopathic intracranial hypertension (IIH) in Chronic daily headache (CDH) - *G. Demonte, L. Rapisarda, F. Tosto, F. Roccia, M. Sturniolo, A. Gambardella, F. Bono*

SCREEN E

- 13:00 - 14:00 **P141** - Loss of periventricular white matter microstructure integrity in idiopathic intracranial hypertension - *Laura Rapisarda, Giulio Demonte, Federico Tosto, Maria Curcio, Alessia Sarica, Antonio Cerasa, Antonio Gambardella, Francesco Bono*
- P142** - Quality of life in the active phase of cluster headache - *Ertsey C, Dióssy M, Magyar M, Gyüre T, Csépany É, Bozsik Gy*
- P143** - Self-detoxification from medication overuse reduces disability among patients with MOH - *Espen Saxhaug Kristoffersen, Ragnhild Berling Grande, Kjersti Aaseth, Michael Bjørn Russell, Christofer Lundqvist*
- P144** - Effects of non-invasive vagus nerve stimulation (nVNS) on resting-state EEG and laser-evoked potentials in migraine: findings from a subgroup of patients enrolled in the randomised, sham-controlled, double-blind PRESTO study - *Eric Liebler, Eleonora Vecchio, Igege Bassez, Katia Ricci, Cristina Tassorelli, Eric Liebler, Marina de Tommaso*
- P145** - Migraine, thrombophilic alterations, and vascular disease: results from a case control study - *Cinzia Cavestro, Diana Degan, Gianmatteo Micca, Raffaele Aloj, Silvia Mandrino, Carlo Di Pietrantonj, Maria Cristina Frigeri, Francesca Pistoia, Filippo Molinari, Simona Sacco*
- P146** - Healthcare Resource Utilisation in Patients Treated with OnabotulinumtoxinA for Chronic Migraine: The REPOSE study - *Monica Elmore, Katja Kollwe, Angela Antonakakis, Katherine Sommer, Justin S. Yu*
- P147** - Proposed new diagnostic criteria for chronic migraine - *Mona Ameri Chalmer, Thomas Folkmann Hansen, Elena Lebedeva, David Dodick, Jes Olesen*
- P148** - Safety and efficacy of cervical 10 kHz cervical spinal cord stimulation (SCS) for the management of refractory chronic migraine: a prospective, proof-of-concept open label study - *Lambru Giorgio, Al-Kaisy Adnan, Palmisani Stefano, Carganillo Roy, Wesley Samuel, Pang David*
- P157** - Efficacy and safety of external trigeminal neurostimulation with the Cefaly® device in chronic migraine: an open trial - *Schoenen Jean, Marius Birlea*
- P158** - Abortive home treatment of migraine with external trigeminal neurostimulation using the Cefaly® device: a pilot trial - *Schoenen Jean, Joseph Mann*

SCREEN A

11:00 - 11:30 **P151** - A multicentre, double-blind, randomised, sham-controlled study of non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the PREMIUM trial - Eric Liebler, Hans-Christoph Diener; Peter J. Goadsby; Messoud Ashina; Mohammad Al-Mahdi Al-Karagholi; Alexandra Sinclair; Dimos Mitsikostas; Delphine Magis; Patricia Pozo-Rosich; Pablo Irimia Sieira; Miguel J.A. Lainez; Charly Gaul; Nicholas Silver; Jan Hoffmann; Eric Liebler; Michel D. Ferrari

P152 - Post hoc analysis of the effects of more frequent non-invasive vagus nerve stimulation (nVNS) for patients with chronic cluster headache from the PREVA trial - Charly Gaul; Eric Liebler; Candace McClure; Annelie Andersson; Andreas Straube

P153 - Impact of medical care on symptomatic drug consumption and quality of life in headache: a one-year population study - Antonaci F, Cotta Ramusino M, Perini G, Vanacore N, Costa A

P154 - Habituation determined by algometry as a marker of response in Chronic Migraine - García-Azorín D, Ruiz-Piñero M, Sierra A, Martínez B, Guerrero Peral AL.

P155 - Study on the phenotypic characterization of delayed alcohol induced headache: series of 1184 sufferers - García-Azorín D, Aparicio Cordero L, Sierra Mencía A, Guerrero Peral AL

SCREEN B

11:00 - 11:30 **P149** - Is pituitary screening necessary in cluster headache? - Lou Grangeon, Emer O'Connor, Daisuke Danno, Thanh Mai Pham Ngoc, Indran avagnanam, Manjit Matharu

P150 - The impact on physician prescribing of monthly and quarterly dosing options for a new class of migraine preventive therapy - Robert Cowan, Erik Rosenman, Tim Fitzgerald, Joshua Cohen, Ravi Iyer

P156 - Ibuprofen and not paracetamol as first line analgesic for acute migraine due to its interaction with TRPA1 in the cinnamaldehyde target engagement biomarker model - Dorien Bamps, Laura Macours, Linde Buntinx, Jan de Hoon

P160 - Prevalence and clinical profile of migraine with aura in a cohort of young patients with minor stroke: a retrospective analysis - Claudia Altamura, Angelo Cascio Rizzo, Matteo Paolucci, Nicoletta Brunelli, Gianluca Cecchi, Fabrizio Vernieri

SCREEN C

11:00 - 11:30 **P161** - The increase of subcutaneous abdominal and body fat is a characteristic associated to allodynia in migraineurs - *Mínguez-Olaondo A, Romero S, Frühbeck G, Martínez-Vila E, Irimia P*

P162 - Clinical profile of migraine with aura and patent foramen ovale: a retrospective analysis - *Claudia Altamura, Nicoletta Brunelli, Gianluca Cecchi, Angelo Cascio Rizzo and Fabrizio Vernieri*

P163 - The Association Between Low Carbohydrate Diet Score and Migraine - *Mansoureh Togha, Soodeh Razeghi Jahromi, Zeinab Ghorbani, Mansoureh Togha, Azita Hekmatdoost, Faezeh Khorsha, Boshra Torkan, Nasim Rezaeimanesh*

P164 - The expanding burden of Idiopathic Intracranial Hypertension - *Susan P Mollan, Magda Aguiar, Felicity Evison, Emma Frew, Alexandra J Sinclair*

P165 - The Number of Active and Latent Trigger Points is Associated with Restricted Cervical Range of motion in Tension Type Headache - *César Fernández-de-las-Peñas, María Palacios-Ceña, Stella Fuensalida-Novo, Matteo Castaldo, Kelun Wang, Lars Arendt-Nielsen, César Fernández-de-las-Peñas*

SCREEN D

11:00 - 11:30 **P166** - Evaluation of the 6-Item Identify Chronic Migraine (ID-CM) Screener in a Large Medical Group - *Monica Elmore, Jelena M. Pavlovic, Justin S. Yu, Stephen D. Silberstein, Michael L. Reed, Steve H. Kawahara, Robert P. Cowan, Firas Dabbous, Karen L. Campbell, Riya Pulicharam, Hema N. Viswanathan, Richard B. Lipton*

P167 - Headache in pharmacy: observational study of pharmacological habit of cephalalgic patient - *Giorgio Dalla Volta, Giorgio Zanchin, Maria Pia Prudenzeno, Lidia Savi*

P168 - The Italian chRONic migraiNe (IRON) Registry: first report from 28 headache centers - *P. Barbanti, Luisa Fofi, Gabriella Egeo, Cinzia Aurilia, Sabina Cevoli, Giulia Pierangeli, Paola Torelli, Giancamillo Manzoni, Cecilia Camarda, Licia Grazi, Domenico D'Amico, Fabrizio Vernieri, Patrizia Balsamo, Fabio Frediani, Giacomo D'Arrigo, Paola Di Fiore, Cinzia Finocchi, Francesco Perini, Florindo d'Onofrio, Francesco Bono, Antonio Russo, Roberto De Simone, Guido Ferra, Vincenzo Busillo, Antonio Carnevale, Francesco Pierelli, Cherubino Di Lorenzo, Fabio Valguarnera, Renata Rao, Salvatore Caratozzolo, Stefano Messina, Bruno Colombo, Alfonso Coppola, Gabriella Turano, Giovanni Battista Allais, Chiara Lia, Ottavio Di Marco, Marcella Curone, Gennaro Bussone, Vincenzo Tullo, Maria Gabriella Saracco, Nicola Vanacore*

SCREEN D

11:00 - 11:30 **P169** - Spontaneous intracranial hypotension in a patient with meningeal diverticula: a case report - *Angelo Torrente Torrente A, Davì M, Pilati L, Portera E, Scardina S, Di Marco S, Gangitano M, Cosentino G, Fierro B, Brighina F.*

P170 - Estimation of the Economic Burden and Labor Impact of Migraine in Spain: Results from the Spanish Atlas of Migraine Survey 2018 - *Pablo Irimia, Marco Garrido-Cumbrera, Sonia Santos-Lasaosa, Isabel Colomina, Francisco Javier León, Carles Blanch, Patricia Pozo-Rosich*

SCREEN E

11:00 - 11:30 **P171** - Chromig10: evolution of migraine after 10 years - *Edoardo Caronna, E. Fonseca Hernández; VJ. Gallardo; JB. Gomez; A. Alpuente; M. Torres-Ferrús; P. Pozo-Rosich*

P172 - Whole Grain Cereal Consumption reduces migraine related disability - *Claudia Altamura, Gianluca Cecchi, Giorgia Botti, Maria Bravo, Paola Di Caprio, Nicoletta Brunelli, Matteo Paolucci, Manon Khazrai and Fabrizio Vernieri*

P173 - The Association Between Dietary Tryptophan Intake and Migraine - *Mansoureh Togha, Soodeh Razeghi Jahromi, Mansoureh Togha, Zeinab Ghorbani, Hossein Ansari, Azita Hekmatdoost, Faezeh Khorsha, Pedram Shirani, Morvarid Nourmohammadi*

P174 - Serum Vitamin B12 and Methyl-malonic Acid Status in a group of Migraine Patients Compared to Healthy Controls: A Case-Control Study - *Mansoureh Togha, Soodeh Razeghi Jahromi, Zeinab Ghorbani, Fahimeh Martami, Maryam Seifishahpar*

P175 - Preliminary efficacy study in prophylaxes of episodic tension cephalo and hemicrania without aura using a combination of Magnesium, L-Triptofano, Boswellia Serrata Casperome[®], Niacina, Riboflavina and Vitamin D compared with Amitriptiline - *Luigi Balzano, B. Ciccone*



EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS) EUROPEAN ACCREDITATION COUNCIL ON CME (EACCME®)

The 12th European Headache Federation Congress, Florence, Italy, 28/09/2018-30/09/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC® s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.” “Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international activities. “Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”

